Alkem Laboratories Ltd

Alkem Laboratories Ltd

₹ 4,959 1.75%
10 Jun - close price
About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Key Points

Leading Pharmaceutical company[1]
Alkem Laboratories holds a 4.1% market share in the Indian domestic formulation market as of 9M FY25, making it the 5th largest pharmaceutical company in India. The company maintains its #1 position in anti-infectives and has a strong presence in gastrointestinal, pain management, vitamins, minerals, and nutrients segments while also expanding in chronic therapies like neurology, cardiology, and diabetology.

  • Market Cap 59,281 Cr.
  • Current Price 4,959
  • High / Low 6,440 / 4,492
  • Stock P/E 27.4
  • Book Value 1,002
  • Dividend Yield 0.81 %
  • ROCE 20.4 %
  • ROE 19.4 %
  • Face Value 2.00

Pros

  • Company has been maintaining a healthy dividend payout of 37.4%

Cons

  • Promoter holding has decreased over last quarter: -0.53%
  • The company has delivered a poor sales growth of 9.21% over past five years.
  • Tax rate seems low

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
2,484 2,576 3,079 3,041 2,903 2,968 3,440 3,324 2,936 3,032 3,415 3,374 3,144
2,147 2,373 2,625 2,442 2,549 2,579 2,693 2,616 2,534 2,423 2,662 2,615 2,752
Operating Profit 337 203 454 599 353 389 747 708 402 609 753 759 391
OPM % 14% 8% 15% 20% 12% 13% 22% 21% 14% 20% 22% 23% 12%
6 51 51 45 -34 66 6 42 76 120 134 93 146
Interest 17 26 25 27 29 30 30 25 27 29 28 36 28
Depreciation 83 76 77 78 78 72 74 70 83 80 79 85 112
Profit before tax 243 152 402 539 212 353 648 655 367 619 780 731 396
Tax % 55% 13% 14% 15% 68% 18% 5% 8% 17% 11% 10% 12% 18%
108 131 348 460 68 288 615 604 304 550 702 641 322
EPS in Rs 9.00 10.68 27.67 38.03 5.94 23.98 51.90 49.76 24.55 45.60 57.60 52.34 25.58
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
3,113 3,674 4,905 5,688 6,401 7,357 8,344 8,865 10,634 11,599 12,668 12,965
2,700 3,248 4,038 4,687 5,392 6,237 6,868 6,920 8,580 9,977 10,419 10,452
Operating Profit 413 427 866 1,001 1,009 1,120 1,476 1,945 2,054 1,622 2,249 2,512
OPM % 13% 12% 18% 18% 16% 15% 18% 22% 19% 14% 18% 19%
162 176 227 110 115 82 102 230 146 101 186 494
Interest 93 81 71 45 55 55 65 59 52 107 112 122
Depreciation 52 71 93 101 143 193 253 275 304 310 299 357
Profit before tax 430 451 928 965 926 955 1,260 1,842 1,844 1,305 2,023 2,527
Tax % -1% 13% 19% 6% 31% 19% 9% 12% 9% 23% 10% 12%
435 392 752 905 638 774 1,149 1,618 1,680 1,007 1,811 2,215
EPS in Rs 364.10 32.75 62.02 74.61 52.77 63.61 94.26 132.57 137.63 82.31 150.19 181.11
Dividend Payout % 5% 12% 20% 20% 25% 25% 27% 23% 25% 61% 27% 25%
Compounded Sales Growth
10 Years: 13%
5 Years: 9%
3 Years: 7%
TTM: 2%
Compounded Profit Growth
10 Years: 20%
5 Years: 14%
3 Years: 9%
TTM: 14%
Stock Price CAGR
10 Years: %
5 Years: 16%
3 Years: 17%
1 Year: -1%
Return on Equity
10 Years: 19%
5 Years: 19%
3 Years: 17%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 12 24 24 24 24 24 24 24 24 24 24 24
Reserves 2,567 2,975 3,668 4,444 4,840 5,415 6,137 7,353 8,614 9,021 10,288 11,961
1,128 1,306 658 659 998 944 1,616 1,792 2,668 1,397 1,418 1,381
604 986 1,184 1,440 1,803 1,824 2,169 2,351 2,763 3,315 3,844 4,325
Total Liabilities 4,311 5,291 5,534 6,568 7,664 8,208 9,946 11,519 14,069 13,757 15,575 17,691
1,170 1,374 1,450 1,797 2,284 2,530 2,908 2,793 2,902 2,683 2,873 2,924
CWIP 0 111 172 299 381 493 363 393 339 323 159 477
Investments 588 481 509 553 444 324 261 333 371 622 484 1,846
2,553 3,325 3,403 3,918 4,555 4,861 6,413 8,000 10,457 10,129 12,060 12,445
Total Assets 4,311 5,291 5,534 6,568 7,664 8,208 9,946 11,519 14,069 13,757 15,575 17,691

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
290 325 726 471 266 780 585 1,265 1,111 1,682 1,948 1,913
353 -235 205 -294 -351 -318 -737 -995 -1,433 120 -1,011 -1,299
-600 -52 -927 -138 85 -379 79 -272 380 -1,761 -1,145 -811
Net Cash Flow 44 39 3 40 0 82 -73 -2 58 42 -207 -197

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 43 52 42 46 62 62 72 66 65 67 65 69
Inventory Days 163 169 169 198 221 186 198 241 262 194 197 224
Days Payable 81 101 108 122 147 119 104 112 102 87 129 141
Cash Conversion Cycle 126 121 103 122 135 129 167 196 225 174 132 152
Working Capital Days 74 60 48 65 84 88 109 117 120 107 169 172
ROCE % 14% 12% 23% 21% 17% 16% 18% 22% 18% 14% 20% 20%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
57.14% 57.16% 57.16% 57.16% 57.16% 56.74% 56.74% 56.74% 56.38% 55.66% 55.66% 55.13%
5.67% 4.46% 4.41% 4.44% 5.63% 6.03% 8.49% 9.11% 8.69% 9.02% 10.14% 9.40%
14.10% 15.73% 16.44% 16.69% 16.34% 17.63% 15.91% 15.63% 18.56% 19.21% 18.01% 19.42%
23.09% 22.65% 21.99% 21.69% 20.85% 19.58% 18.86% 18.51% 16.37% 16.12% 16.19% 16.05%
No. of Shareholders 84,10479,72176,51673,44066,79069,44265,18465,83069,62774,74484,03884,326

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls